AlloVir, Inc.

Equities

ALVR

US0198181036

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 31/05/2024 BST			5-day change	1st Jan Change
0.7549 ^USD	+1.00%		-0.28%	+11.05%

05-13	AlloVir, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-20	North American Morning Briefing : Markets on Hold -2-	DJ

AlloVir, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022

February 15, 2023 at 01:32 pm

AlloVir, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 168.71 million compared to USD 171.96 million a year ago. Basic loss per share from continuing operations was USD 2.2 compared to USD 2.74 a year ago.

Latest news about AlloVir, Inc.

AlloVir, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
North American Morning Briefing : Markets on Hold -2-	03-20	DJ
AlloVir, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-15	CI
North American Morning Briefing : Stock Futures -2-	03-13	DJ
North American Morning Briefing : Stock Futures -2-	02-21	DJ
North American Morning Briefing : S&P 500 Hovers Near Record as Interest Rate Optimism Holds Sway	12-27	DJ
Sector Update: Health Care	12-22	MT
Morgan Stanley Downgrades AlloVir to Equalweight From Overweight, Cuts Price Target to $1 From $20	12-22	MT
AlloVir Shares Plummet as Global Trials of Anti-Viral T-Cell Therapy to be Discontinued	12-22	MT
Top Midday Decliners	12-22	MT
Sector Update: Health Care Stocks Gain in Late Afternoon	12-22	MT
AlloVir to Review Strategic Alternatives for the Company and Its Portfolio of Virus-Specific T Cell Therapies	12-22	CI
AlloVir scraps late-stage studies testing lead cell therapy	12-22	RE
AlloVir scraps late-stage studies testing antiviral cell therapy	12-22	RE
AlloVir, Inc. Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy	12-22	CI
Leerink Partners Downgrades AlloVir to Market Perform From Outperform, Cuts Price Target to $1 From $14	12-22	MT
Piper Sandler Downgrades AlloVir to Neutral From Overweight, Cuts Price Target to $1.50 From $27	12-22	MT
JPMorgan Downgrades AlloVir to Underweight From Overweight	12-22	MT
AlloVir, Inc.(NasdaqGS:ALVR) dropped from NASDAQ Biotechnology Index	12-15	CI
AlloVir, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-02	CI
Certain Restricted Stock Units of AlloVir, Inc. are subject to a Lock-Up Agreement Ending on 20-SEP-2023.	19/09/23	CI
Certain Stock Options of AlloVir, Inc. are subject to a Lock-Up Agreement Ending on 20-SEP-2023.	19/09/23	CI
Certain Common Stock of AlloVir, Inc. are subject to a Lock-Up Agreement Ending on 20-SEP-2023.	19/09/23	CI
Transcript : AlloVir, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-11-2023 04:55 PM	11/09/23
Sector Update: Health Care Stocks Declining Late Afternoon	18/08/23	MT

Chart AlloVir, Inc.

Duration

Period

More charts

Company Profile

AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The companyâs proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.

Sector

Biotechnology & Medical Research

Calendar

05/06/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

0.7549 USD

Average target price

0.975 USD

Spread / Average Target

+29.16%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ALLOVIR, INC.	+11.05%	84.78M
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	114B
REGENERON PHARMACEUTICALS, INC.	+11.60%	105B
BIONTECH SE	-4.68%	23.83B
ARGENX SE	-0.82%	21.73B
GENMAB A/S	-10.12%	18.1B
WUXI APPTEC CO., LTD.	-42.12%	16.34B
BEIGENE, LTD.	-17.47%	16.13B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.75B
SAREPTA THERAPEUTICS, INC.	+34.58%	11.76B

Bio Therapeutic Drugs